Strategies for monitoring outcomes in patients with bipolar disorder

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 12, Issue SUPPL. 1, 2010, Pages 10-16

  Ketter, Terence A ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

AGRANULOCYTOSIS; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; BIPOLAR DISORDER; BLOOD DYSCRASIA; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; COMORBIDITY; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG LABELING; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE ORGANIZATION; HUMAN; HYPERGLYCEMIA; HYPOMANIA; INTERPERSONAL COMMUNICATION; LEUKOPENIA; LIVER DISEASE; MANIA; MEDICAL DECISION MAKING; METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD DISORDER QUESTIONNAIRE; MORBIDITY; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; NEUTROPENIA; OBESITY; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT COMPLIANCE; PATIENT HEALTH QUESTIONNAIRE; PATIENT MONITORING; PHYSICIAN ATTITUDE; PRIMARY MEDICAL CARE; PSYCHOEDUCATION; PSYCHOLOGIC ASSESSMENT; PSYCHOTHERAPY; QUESTIONNAIRE; RASH; RESTLESSNESS; SEDATION; SELF REPORT; SENSITIVITY ANALYSIS; SIDE EFFECT; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA; TERATOGENICITY; TREMOR; UNITED STATES; UNSTEADINESS; VOMITING; WEIGHT GAIN;

EID: 78650547482     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.9064su1c.02     Document Type: Article

References (42)

1. Brieger P, Röttig S, Röttig D, et al. Dimensions underlying outcome criteria in bipolar I disorder. J Affect Disord. 2007;99(1-3):1-7. PubMed doi:10.1016/j.jad.2006.08.012
2. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261-269. PubMed doi:10.1001/archpsyc.60.3.261
3. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537. PubMed doi:10.1001/archpsyc.59.6.530
4. Pfizer Incorporated. Patient Health Questionnaire (PHQ-9). http://www.cqaimh.org/pdf/tool_depscreen. Published 2005. Accessed March 3, 2010.
5. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. PubMed doi:10.1046/j.1525-1497.2001.016009606.x
6. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561-571. PubMed
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
8. Hirschfeld RMA, Williams JBW, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157(11):1873-1875. PubMed doi:10.1176/appi.ajp.157.11.1873
9. Manning JS. Tools to improve differential diagnosis of bipolar disorder in primary care. Prim Care Companion J Clin Psychiatry. 2010;12(suppl 1):17-22.
10. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry. 2001;158(3):420-426. PubMed doi:10.1176/appi.ajp.158.3.420
11. McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Hum Psychopharmacol. 2004;19(6):369-386. PubMed doi:10.1002/hup.612
12. Krishnan KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67(1):1-8. PubMed doi:10.1097/01.psy.0000151489.36347.18
13. Solomon DA, Keitner GI, Miller IW, et al. Course of illness and maintenance treatments for patients with bipolar disorder. J Clin Psychiatry. 1995;56(1):5-13. PubMed
14. Velligan DI, Weiden PJ, Sajatovic M, et al, for the Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46. PubMed
15. Altman S, Haeri S, Cohen LJ, et al. Predictors of relapse in bipolar disorder: a review. J Psychiatr Pract. 2006;12(5):269-282. PubMed doi:10.1097/00131746-200609000-00002
16. Keck PE Jr, McElroy SL, Strakowski SM, et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry. 1996;57(7):292-297. PubMed
17. Colom F, Vieta E, Martínez-Arán A, et al. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry. 2000;61(8):549-555. PubMed
18. Jamison KR, Gerner RH, Goodwin FK. Patient and physician attitudes toward lithium: relationship to compliance. Arch Gen Psychiatry. 1979;36(8 spec no):866-869.
19. Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. J Clin Psychiatry. 2005;66(suppl 1):24-29. PubMed
20. Lenzi A, Lazzerini F, Placidi GF, et al. Predictors of compliance with lithium and carbamazepine regimens in the long-term treatment of recurrent mood and related psychotic disorders. Pharmacopsychiatry. 1989;22(1):34-37. PubMed doi:10.1055/s-2007-1014574
21. Keck PE Jr, McElroy SL, Strakowski SM, et al. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull. 1997;33(1):87-91. PubMed
22. Ketter TA, ed. Handbook of Diagnosis and Treatment of Bipolar Disorder. Washington, DC: American Psychiatric Publishing Inc; 2010.
23. Lithobid (lithium carbonate) [package insert]. Miami, FL: Noven Therapeutics; April 2008. http://www.noven.com/products.htm. Accessed February 9, 2010.
24. Depakote (divalproex sodium) [package insert]. North Chicago, IL: Abbott Laboratories; November 2009. www.rxabbott.com/pdf/depakote.pdf. Accessed February 9, 2010.
25. Depacon (valproate sodium injection) [package insert]. North Chicago, IL: Abbott Laboratories; November, 2009. www.rxabbott.com/pdf/depacon.pdf. Accessed March 5, 2010.
26. Tegretol (carbamazepine) [package insert]. East Hanover, NJ: Novartis; February 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016608s101,018281s048lbl.pdf. Accessed February 9, 2010.
27. Lamictal (lamotrigine) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; May 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022251,020764s029,020241s036lbl.pdf. Accessed February 9, 2010.
28. Haldol (haloperidol) [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc; June 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018701s059lbl.pdf. Accessed February 12, 2010.
29. Navane (thiothixene) [package insert]. New York, NY: Pfizer Inc; June 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016584s059lbl.pdf. Accessed February 12, 2010.
30. Saphris (asenapine) [package insert]. Kenilworth, NJ: Schering-Plough; August 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022117s000lbl.pdf. Accessed February 12, 2010.
31. Abilify (aripiprazole) [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Company; November 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021436s027lbl.pdf. Accessed February 9, 2010.
32. Zyprexa (olanzapine) [package insert]. Indianapolis, IN: Eli Lilly and Company; January 2010. http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed February 9, 2010.
33. Symbyax (olanzapine and fluoxetine hydrochloride) [package insert]. Indianapolis, IN: Eli Lilly and Company; January 2010. http://pi.lilly.com/us/symbyax-pi.pdf. Accessed February 9, 2010.
34. Seroquel (quetiapine) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020639s045s046lbl.pdf. Accessed February 9, 2010.
35. Risperdal (risperidone) [package insert]. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc; June 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf. Accessed February 9, 2010.
36. Geodon (ziprasidone) [package insert]. New York, NY: Pfizer Inc; November 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020825s034lbl.pdf. Accessed February 12, 2010.
37. US Food and Drug Administration. Revisions to Product Labeling. Rockville, MD: US Food and Drug Administration; 2007. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf. Accessed February 9, 2010.
38. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850. PubMed doi:10.1001/archpsyc.58.9.844
39. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7(5):424-430. PubMed doi:10.1111/j.1399-5618.2005.00234.x
40. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601. PubMed doi:10.2337/diacare.27.2.596
41. Boehm G, Racoosin JA, Laughren TP, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement [letter]. Diabetes Care. 2004;27(8):2088-2089. PubMed doi:10.2337/diacare.27.8.2088-a
42. Culpepper L. The role of primary care clinicians in diagnosing and treating bipolar disorder. Prim Care Companion J Clin Psychiatry. 2010;12(suppl 1):4-9.